Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

MK-6070

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

Roche’s small cell lung cancer therapy approved by FDA

This is the first and only approved combination therapy for extensive-stage small cell lung cancer

- PMLiVE

Ipsen’s tumour treatment receives MHRA marketing authorisation

This is the first approval in the UK for previously treated advanced neuroendocrine tumours

- PMLiVE

David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare

Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site

- PMLiVE

Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours

Treatment options following disease progression have previously been limited for many patients

- PMLiVE

Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours

The number of patients newly diagnosed with NETs is believed to be on the rise

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

- PMLiVE

AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

Around one in three patients with early-stage breast cancer are considered high risk

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer

Up to 20% of patients with metastatic breast cancer are affected by HER2-positive disease

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer

Approximately 557,000 people are diagnosed with breast cancer every year in Europe

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer

Approximately 557,000 people are diagnosed with breast cancer every year in Europe

- PMLiVE

BeiGene’s Tevimbra recommended by CHMP to treat small cell lung cancer

The aggressive form of lung cancer accounts for around 15% of all cases of the disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links